KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Bio-Rad Laboratories (BIO) EBIAT (2016 - 2026)

Bio-Rad Laboratories has reported EBIAT over the past 18 years, most recently at -$527.1 million for Q1 2026.

  • Quarterly EBIAT fell 923.59% to -$527.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $168.8 million through Mar 2026, up 107.8% year-over-year, with the annual reading at $759.9 million for FY2025, 141.2% up from the prior year.
  • EBIAT was -$527.1 million for Q1 2026 at Bio-Rad Laboratories, down from $720.0 million in the prior quarter.
  • Over five years, EBIAT peaked at $827.7 million in Q4 2022 and troughed at -$3.4 billion in Q1 2022.
  • The 5-year median for EBIAT is $64.0 million (2025), against an average of -$345.7 million.
  • Year-over-year, EBIAT soared 514.49% in 2024 and then crashed 923.59% in 2026.
  • A 5-year view of EBIAT shows it stood at $827.7 million in 2022, then tumbled by 57.75% to $349.7 million in 2023, then crashed by 304.69% to -$715.8 million in 2024, then skyrocketed by 200.59% to $720.0 million in 2025, then tumbled by 173.21% to -$527.1 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's EBIAT are -$527.1 million (Q1 2026), $720.0 million (Q4 2025), and -$341.9 million (Q3 2025).